MXPA04006027A - Metodo para el tratamiento de trastornos de los huesos. - Google Patents

Metodo para el tratamiento de trastornos de los huesos.

Info

Publication number
MXPA04006027A
MXPA04006027A MXPA04006027A MXPA04006027A MXPA04006027A MX PA04006027 A MXPA04006027 A MX PA04006027A MX PA04006027 A MXPA04006027 A MX PA04006027A MX PA04006027 A MXPA04006027 A MX PA04006027A MX PA04006027 A MXPA04006027 A MX PA04006027A
Authority
MX
Mexico
Prior art keywords
bone disorders
disclosed
treatment
methods
loading
Prior art date
Application number
MXPA04006027A
Other languages
English (en)
Inventor
Arkadi Aaron Chines
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04006027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MXPA04006027A publication Critical patent/MXPA04006027A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Se describen metodos para el tratamiento de trastornos de los huesos en mamiferos. Los metodos comprenden un periodo de carga con bifosfonato seguido por un periodo de mantenimiento. La dosis de carga diaria es de dos a veinte veces mayor que la dosis de mantenimiento correspondiente. Tambien se describen composiciones y estuches para implementar los metodos descritos en la presente.
MXPA04006027A 2001-12-21 2002-12-16 Metodo para el tratamiento de trastornos de los huesos. MXPA04006027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21
PCT/US2002/040234 WO2003055496A1 (en) 2001-12-21 2002-12-16 Method for the treatment of bone disorders

Publications (1)

Publication Number Publication Date
MXPA04006027A true MXPA04006027A (es) 2004-09-27

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006027A MXPA04006027A (es) 2001-12-21 2002-12-16 Metodo para el tratamiento de trastornos de los huesos.

Country Status (24)

Country Link
US (5) US20030118634A1 (es)
EP (1) EP1455796A1 (es)
JP (1) JP2005514400A (es)
KR (1) KR100638122B1 (es)
CN (1) CN100479823C (es)
AR (1) AR038041A1 (es)
AU (1) AU2002360619B2 (es)
CA (1) CA2469779C (es)
CZ (1) CZ2004690A3 (es)
HK (1) HK1087039A1 (es)
HU (1) HUP0402267A3 (es)
IL (2) IL162053A0 (es)
MA (1) MA27157A1 (es)
MX (1) MXPA04006027A (es)
MY (1) MY147886A (es)
NO (1) NO340249B1 (es)
NZ (1) NZ532994A (es)
PE (1) PE20030743A1 (es)
PL (1) PL371264A1 (es)
RU (1) RU2294203C2 (es)
SK (1) SK2532004A3 (es)
TW (1) TWI349553B (es)
WO (1) WO2003055496A1 (es)
ZA (1) ZA200404007B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
PT1596870E (pt) * 2002-12-20 2007-10-15 Hoffmann La Roche Formulação com uma dose elevada de ibandronato
DE602005022578D1 (de) * 2004-05-24 2010-09-09 Warner Chilcott Co Llc Enterische feste orale dosierform eines bisphosphonats mit einem chelate
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
GB2217988B (en) * 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (es) * 1992-04-15 1995-01-01 Ciba Geigy
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
RU2126414C1 (ru) * 1992-05-29 1999-02-20 Дзе Проктер энд Гэмбл Фармасьютикалз, Инк. Содержащие четвертичный азот фосфонаты для лечения анормального кальциевого и фосфатного метаболизма, а также профилактики и лечения зубных налетов и зубных камней, фармацевтические композиции и способ лечения
ATE179329T1 (de) * 1992-06-30 1999-05-15 Procter & Gamble Pharma Arzneimitteln zur behandlung von arthritis die phosphonate und nsaids enthalten
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
ATE309330T1 (de) * 1995-06-07 2005-11-15 Co Don Ag Verfahren zur osteoporosediagnose und zur testung potentieller osteoporose-therapeutika unter verwendung von standardisierten, primären osteoblastenzellkulturen aus osteoporotischen patienten
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6432931B1 (en) * 1998-06-24 2002-08-13 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
ES2247842T3 (es) * 1998-12-04 2006-03-01 Roche Diagnostics Gmbh Uso de ibandronato para promover la oseo-integracion de endoprotesis.
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AU2001271055B2 (en) * 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
JP2004504351A (ja) * 2000-07-19 2004-02-12 イーライ・リリー・アンド・カンパニー 骨量増加の増強方法
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
KR20030072399A (ko) * 2001-02-06 2003-09-13 더 로얄 알렉산드라 호스피탈 포 칠드런 골괴사 치료용 및 골괴사 발현의 위험이 있는 환자의처리용 약제
AU2002254082B2 (en) * 2001-03-01 2007-05-24 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
AU2002305359B2 (en) * 2001-05-10 2005-05-26 Merck & Co., Inc. Estrogen receptor modulators
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
US20080260827A1 (en) 2008-10-23
CN1723024A (zh) 2006-01-18
AU2002360619A1 (en) 2003-07-15
US20070166237A1 (en) 2007-07-19
HUP0402267A2 (hu) 2005-02-28
AU2002360619B2 (en) 2006-10-05
CZ2004690A3 (cs) 2004-09-15
AR038041A1 (es) 2004-12-22
PE20030743A1 (es) 2003-10-22
KR20040065283A (ko) 2004-07-21
IL162053A (en) 2009-09-22
US20030118634A1 (en) 2003-06-26
KR100638122B1 (ko) 2006-10-24
MA27157A1 (fr) 2005-01-03
WO2003055496A1 (en) 2003-07-10
NZ532994A (en) 2008-05-30
US20080261924A1 (en) 2008-10-23
US20080214505A1 (en) 2008-09-04
RU2294203C2 (ru) 2007-02-27
JP2005514400A (ja) 2005-05-19
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
CN100479823C (zh) 2009-04-22
RU2004122433A (ru) 2005-03-10
HUP0402267A3 (en) 2007-05-29
MY147886A (en) 2013-01-31
PL371264A1 (en) 2005-06-13
NO340249B1 (no) 2017-03-27
SK2532004A3 (en) 2004-11-03
CA2469779C (en) 2008-02-12
TWI349553B (en) 2011-10-01
CA2469779A1 (en) 2003-07-10
ZA200404007B (en) 2005-07-27
NO20043113L (no) 2004-09-01
TW200301704A (en) 2003-07-16
IL162053A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
HK1104836A1 (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
HK1156515A1 (en) Pharmaceutical compositions and methods for accelerating wound healing
PT1365762E (pt) Processo para aumentar os níveis de leptina utilizando compostos do ácido nicotínico
MX2009001342A (es) Composiciones y metodos para el tratamiento de proctosigmoiditis por radiacion.
DK2198876T3 (da) Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ
AU2003208567A8 (en) Methods of inducing differentiation in stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem cells, methods of producing adult stem cells and methods of continuously generating stem cells by implantation of micro-organs as sources of stem cells
WO2003094837A3 (en) Treatments with autologous fibroblast
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
MY147886A (en) Method for the treatment of bone disorders
EP1896581A4 (en) MATERIALS, COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING IMMUNE-MEDIATED INFLAMMATORY DISORDERS
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
HK1087328A1 (en) Therapeutic composition for autoimmune conditions
AU2003304173A8 (en) Compositions and methods for promoting neuronal outgrowth
TR200200278T2 (tr) Kalsilitik bileşimler
AU2003239813A1 (en) Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori
EP0904094A4 (en) TREATMENT OF BONE DISEASES USING ADRENOMEDULLINE
GB9500024D0 (en) Treatment of excessive cell proliferation disorders
EP1546100A4 (en) NEW BENZOYLPIPERIDINE COMPOUNDS
BR0215026A (pt) Método para o tratamento de desordens ósseas

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: WARNER CHILCOTT COMPANY, LLC

FC Refusal